MiRNA Expression and Function in Thyroid Carcinomas: a Comparative and Critical Analysis and a Model for Other Cancers

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Jun 2

PMID 27248468

Citations 18

Authors

Manuel Saiselet

Jaime M Pita

Alice Augenlicht

Genevieve Dom

Maxime Tarabichi

Danai Fimereli

Jacques E Dumont

Vincent Detours

Carine Maenhaut

Affiliations

Soon will be listed here.

Abstract

As in many cancer types, miRNA expression profiles and functions have become an important field of research on non-medullary thyroid carcinomas, the most common endocrine cancers. This could lead to the establishment of new diagnostic tests and new cancer therapies. However, different studies showed important variations in their research strategies and results. In addition, the action of miRNAs is poorly considered as a whole because of the use of underlying dogmatic truncated concepts. These lead to discrepancies and limits rarely considered. Recently, this field has been enlarged by new miRNA functional and expression studies. Moreover, studies using next generation sequencing give a new view of general miRNA differential expression profiles of papillary thyroid carcinoma. We analyzed in detail this literature from both physiological and differential expression points of view. Based on explicit examples, we reviewed the progresses but also the discrepancies and limits trying to provide a critical approach of where this literature may lead. We also provide recommendations for future studies. The conclusions of this systematic analysis could be extended to other cancer types.

Citing Articles

Description of a New miRNA Signature for the Surgical Management of Thyroid Nodules.

Quiriny M, Rodrigues Vitoria J, Saiselet M, Dom G, de Saint Aubain N, Willemse E Cancers (Basel). 2025; 16(24.

PMID: 39766113 PMC: 11674976. DOI: 10.3390/cancers16244214.

Understanding the Dosage-Dependent Role of in Thyroid Tumorigenesis.

Rojo-Pardillo M, Godefroid L, Dom G, Lefort A, Libert F, Robaye B Int J Mol Sci. 2024; 25(19).

PMID: 39409030 PMC: 11476720. DOI: 10.3390/ijms251910701.

miR-331-5p Affects Motility of Thyroid Cancer Cell Lines and Regulates BID Expression.

Orlandella F, Imperlini E, Pane K, Luciano N, Braile M, De Stefano A Biomedicines. 2024; 12(3).

PMID: 38540271 PMC: 10968654. DOI: 10.3390/biomedicines12030658.

Circ_0003747 promotes thyroid cancer progression by sponging miR-338-3p to upregulate PLCD3 expression.

Dou X, Xia F, Li X Epigenetics. 2023; 18(1):2210339.

PMID: 37166441 PMC: 10177672. DOI: 10.1080/15592294.2023.2210339.

Recurrence of Papillary Thyroid Cancer: A Systematic Appraisal of Risk Factors.

Nieto H, Thornton C, Brookes K, Nobre de Menezes A, Fletcher A, Alshahrani M J Clin Endocrinol Metab. 2021; 107(5):1392-1406.

PMID: 34791326 PMC: 9016467. DOI: 10.1210/clinem/dgab836.

References

Soon P, Kiaris H . MicroRNAs in the tumour microenvironment: big role for small players. Endocr Relat Cancer. 2013; 20(5):R257-67. DOI: 10.1530/ERC-13-0119. View

Haghpanah V, Fallah P, Tavakoli R, Naderi M, Samimi H, Soleimani M . Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer. Tumour Biol. 2015; 37(1):1299-308. DOI: 10.1007/s13277-015-3923-z. View

Lassalle S, Hofman V, Ilie M, Bonnetaud C, Puissegur M, Brest P . Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?. Endocr Relat Cancer. 2011; 18(5):579-94. DOI: 10.1530/ERC-10-0283. View

He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S . The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102(52):19075-80. PMC: 1323209. DOI: 10.1073/pnas.0509603102. View

Ferracin M, Lupini L, Salamon I, Saccenti E, Zanzi M, Rocchi A . Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget. 2015; 6(16):14545-55. PMC: 4546486. DOI: 10.18632/oncotarget.3859. View

Lee J, Zhao J, Clifton-Bligh R, Gill A, Gundara J, Ip J . MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013; 119(24):4358-65. DOI: 10.1002/cncr.28254. View

Suzuki H, Mihira H, Watabe T, Sugimoto K, Miyazono K . Widespread inference of weighted microRNA-mediated gene regulation in cancer transcriptome analysis. Nucleic Acids Res. 2013; 41(5):e62. PMC: 3597654. DOI: 10.1093/nar/gks1439. View

Callegari E, Elamin B, DAbundo L, Falzoni S, Donvito G, Moshiri F . Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PLoS One. 2013; 8(9):e73964. PMC: 3771938. DOI: 10.1371/journal.pone.0073964. View

Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A . Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 2007; 26(54):7590-5. DOI: 10.1038/sj.onc.1210564. View

10.

Zhang Y, Zhong Q, Chen X, Fang J, Huang Z . Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine-needle aspiration samples. Tumour Biol. 2014; 35(9):9343-53. DOI: 10.1007/s13277-014-2209-1. View

11.

Stokowy T, Wojtas B, Fujarewicz K, Jarzab B, Eszlinger M, Paschke R . miRNAs with the potential to distinguish follicular thyroid carcinomas from benign follicular thyroid tumors: results of a meta-analysis. Horm Metab Res. 2014; 46(3):171-80. DOI: 10.1055/s-0033-1363264. View

12.

Callegari E, Elamin B, Giannone F, Milazzo M, Altavilla G, Fornari F . Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology. 2012; 56(3):1025-33. DOI: 10.1002/hep.25747. View

13.

Riesco-Eizaguirre G, Wert-Lamas L, Perales-Paton J, Sastre-Perona A, Fernandez L, Santisteban P . The miR-146b-3p/PAX8/NIS Regulatory Circuit Modulates the Differentiation Phenotype and Function of Thyroid Cells during Carcinogenesis. Cancer Res. 2015; 75(19):4119-30. DOI: 10.1158/0008-5472.CAN-14-3547. View

14.

Nagaiah G, Hossain A, Mooney C, Parmentier J, Remick S . Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011; 2011:542358. PMC: 3136148. DOI: 10.1155/2011/542358. View

15.

Huang C, Oyang Y, Huang H, Juan H . MicroRNA-mediated networks underlie immune response regulation in papillary thyroid carcinoma. Sci Rep. 2014; 4:6495. PMC: 4178297. DOI: 10.1038/srep06495. View

16.

Frankel L, Christoffersen N, Jacobsen A, Lindow M, Krogh A, Lund A . Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2007; 283(2):1026-33. DOI: 10.1074/jbc.M707224200. View

17.

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

18.

Agretti P, Ferrarini E, Rago T, Candelieri A, De Marco G, Dimida A . MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration. Eur J Endocrinol. 2012; 167(3):393-400. DOI: 10.1530/EJE-12-0400. View

19.

Suzuki H, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K . Modulation of microRNA processing by p53. Nature. 2009; 460(7254):529-33. DOI: 10.1038/nature08199. View

20.

Zhang J, Yang Y, Liu Y, Fan Y, Liu Z, Wang X . MicroRNA-21 regulates biological behaviors in papillary thyroid carcinoma by targeting programmed cell death 4. J Surg Res. 2014; 189(1):68-74. DOI: 10.1016/j.jss.2014.02.012. View